Business Context and Reporting Period
This Form 8-K, dated March 12, 2021, is filed by Big Rock Partners Acquisition Corp. (BRPA), a Delaware corporation and emerging growth company. The filing reports the entry into a Material Definitive Agreement and the sale of unregistered equity securities in connection with a proposed business combination with NeuroRx, Inc. (NeuroRx). Under the terms of the Merger Agreement, a wholly-owned subsidiary of BRPA will merge with NeuroRx, resulting in NeuroRx becoming a wholly-owned subsidiary of BRPA.
Key Financial Metrics and Transaction Details
The filing details a Private Investment in Public Equity (PIPE) transaction rather than historical operating results. Key financial terms include:
- PIPE Investment: BRPA entered into subscription agreements to issue 1,000,000 shares of common stock to qualified institutional buyers and accredited investors.
- Price per Share: $10.00 per share.
- Gross Proceeds: $10,000,000.
- Conditions: The closing is contingent upon the consummation of the Merger, accuracy of representations, and Nasdaq listing approval.
The filing does not provide historical revenue, profit, cash flow, margins, debt, or liquidity metrics for either BRPA or NeuroRx. The registrant is a special purpose acquisition company (SPAC) and NeuroRx is a pre-revenue biopharmaceutical entity; therefore, traditional financial performance metrics are not applicable in this context.
Material Changes and Transaction Structure
The primary material change is the execution of the Subscription Agreements for the PIPE financing. This transaction is designed to provide capital to the combined company immediately following the merger. The shares were sold under Section 4(a)(2) of the Securities Act of 1933, exempt from registration. BRPA has agreed to file a registration statement for the resale of these shares within 45 days of the Merger closing and use best efforts to have it declared effective within 60 days (or 90 days if the SEC issues comments).
Guidance, Risks, and Forward-Looking Statements
The filing contains extensive forward-looking statements regarding the proposed business combination and NeuroRx's drug development pipeline. Management cautions that actual results may differ materially due to significant risks, including:
- Uncertainty regarding the approval, timing, and ability to complete the business combination.
- Risks associated with remaining listed on the Nasdaq Capital Market before and after the transaction.
- Inherent uncertainties in the FDA approval process for NeuroRx's drugs.
- Potential disruption to NeuroRx's operations due to the transaction.
- Impact of the COVID-19 pandemic and other economic factors.
Investors are urged to read the definitive proxy statement/prospectus filed on Form S-4 for detailed risk factors and financial information.
Key Facts for Investor Verification
- Verify the final terms and conditions of the Merger Agreement and the Subscription Agreements attached as exhibits.
- Confirm the status of the Form S-4 registration statement and the proxy statement/prospectus for the proposed business combination.
- Assess the regulatory approval status of NeuroRx's drug candidates, as this is a primary driver of value.
- Monitor the timeline for the filing and effectiveness of the resale registration statement for the PIPE investors.
- Review the full list of risks detailed in the Form S-4 filing, particularly regarding FDA approvals and market conditions.